Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 98, Issue 8, 2003, Pages 1821-1826

  Regueiro, Miguel ^b   Valentine, John ^b   Plevy, Scott ^b   Fleisher, Mark R ^b   Lichtenstein, Gary R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DAPSONE; INFLIXIMAB; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THALIDOMIDE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; INTESTINE RESECTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RECURRENT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DEFECT; SKIN ULCER; SUNBURN; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WOUND CARE;

EID: 0041571851     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07581.x     Document Type: Article

References (28)

1. Callen JP. Pyoderma gangrenosum. Lancet 1998;351:581-5.
2. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149-58.
3. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000;79:37-46.
4. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am J Gastroenterol 2001;96:1116-22.
5. Stenson WF. Inflammatory bowel diseases. In: Yamada T, ed. The textbook of gastroenterology. Philadelphia: Lippincott Williams & Wilkins, 1999:1775-839.
6. Bentley-Phillips CB, Cooper RC, Hallett AF. Pharmacological modulation of neutrophil phagocytic function in a patient with recurrent sepsis, pyoderma gangrenosum and impaired phagocytosis. Br J Dermatol 1982;106:687-95.
7. Adachi Y, Kindzelskii AL, Cookingham G, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 1998;111:259-68.
8. Snyder RA. Pyoderma gangrenosum involving the head and neck. Arch Dermatol 1986;122:295-302.
9. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001;68:287-97.
10. Friedman S, Marion JF, Scherl E, et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001;7:1-7.
11. Alam M, Grossman ME, Schneiderman PI, et al. Surgical management of pyoderma gangrenosum: Case report and review. Dermatol Surg 2000;26:1063-6.
12. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
13. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
14. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
15. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
16. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor a antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
17. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor α monoclonal antibody. Arch Dermatol 2001;137:930-3.
18. Hong JJ, Merel NJ, Hanauer SB. Treatment of pyoderma gangrenosum complicating Crohn's disease with infliximab. Gastroenterology 2001;120:A621 (abstract 3143).
19. Sapienza MS, Cohen S, DiMarino AJ. Improvement of pyoderma gangrenosum after infliximab treatment for fistulizing Crohn's disease. Am J Gastroenterol 2001;96:S307 (abstract 972).
20. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: Effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002;37:1108-10.
21. Holt PJ, Davies MG, Saunders KC, et al. Pyoderma gangrenosum: Clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore) 1980;59:114-33.
22. Hohenleutner U, Mohr VD, Michel S, et al. Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum. Lancet 1997;350:1748.
23. D'Inca R, Fagiuoli S, Sturniolo GC. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Int Med 1998;128:783-4.
24. Schuppe HC, Homey B, Assmann T, et al. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998;351:832.
25. Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000;75:842-4.
26. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
27. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
28. Sands B, Van Deventer S, Bernstein C, et al. Long-term treatment of fistulizing Crohns disease: Response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002;122:A-81 (abstract 671).